Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
COGNITION THERAPEUTICS INC (CGTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/24/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Exhibit 99.1"
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update"
06/12/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
05/01/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment Agreement, by and between Cognition Therapeutics, Inc. and John Doyle"
04/24/2023 ARS Form ARS - Annual Report to Security Holders:
04/24/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/24/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/19/2023 8-K Quarterly results
03/28/2023 8-K Quarterly results
03/27/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/23/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/23/2023 10-K Annual Report for the period ended December 31, 2022
03/23/2023 8-K Quarterly results
Docs: "Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update"
03/15/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Cognition Therapeutics Announces Development Plans for Oral CT1812 in Geographic Atrophy Secondary to Dry AMD , March 15, 2023 — Cognition Therapeutics, Inc. announced that its Investigational New Drug application for investigation of CT1812 for geographic atrophy secondary to dry age-related macular degeneration has been cleared by the U.S. Food and Drug Administration . Cognition plans to initiate the Phase 2 MAGNIFY trial of its oral drug candidate, CT1812 in 2023 in individuals with dry AMD who have measurable GA. “We enjoyed a collaborative dialogue with the ophthalmology division of the FDA during our pre-IND meeting and are excited to assess the potential of CT1812 to impact GA and slow the decline in visual acuity in people with dry AMD,” said Anthony Caggiano, M.D., Ph.D. , Cognit..."
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/10/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/10/2023 8-K Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Financial Statements and Exhibits ...
Docs: "292 Arch Street Suit",
"WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor, and the Investor wishes to buy from the Company, up to Thirty-Five Million Dollars of the Company’ s common stock, $0.001 par value per share . The shares of Common Stock to be purchased hereunder are referred to herein as the " Purchase Shares ." NOW THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and the Investor hereby agree as follows: 1. CERTAIN DEFINITIONS. For purposes of this Agreement, the following terms shall have the following meanings:            &...",
"REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT , dated as of March 10, 2023, is entered into by and between COGNITION THERAPEUTICS, INC., a Delaware corporation , and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company . Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement by and between the parties hereto, dated as of the date hereof . WHEREAS: A.           Upon the terms and subject to the conditions of the Purchase Agreement, the Company has agreed to issue to the Investor, and the Investor has agreed to purchase, up to Thirty-Five Million Dollars of the Company's common stock, par value $0.001 per share , pursua..."
02/22/2023 8-K Quarterly results
02/13/2023 8-K Quarterly results
12/05/2022 SC 13D/A BIOS Memory SPV I, LP reports a 23% stake in Cognition Therapeutics, Inc.
11/18/2022 SC 13G HIRSCHMAN ORIN reports a 7% stake in Cognition Therapeutics, Inc.
11/16/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Exhibit 99.1"
11/07/2022 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
08/29/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Developing disease- modifying medicines for degenerative disorders August 2022"
08/09/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/09/2022 8-K Quarterly results
07/27/2022 8-K Quarterly results
06/16/2022 8-K Quarterly results
06/13/2022 8-K Quarterly results
05/11/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/11/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy